November 12 2014

Successful Clinical Trials for Prof Margaret Brimble's NNZ2566

Neuren Pharma have today released the optimistic results of the drug NNZ2566 being trialled with Rett women in the USA
The next stage is to see FDA approval for Fast Track and/or Orphan status in the first quarter of 2015.
Margaret spoke to our 2014 conference on her discovery.
She said she has always dreamt of discovering a drug that would make a difference.